These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28285118)

  • 61. Left ventricular assist device bridging to heart transplantation: Comparison of temporary versus durable support.
    Hess NR; Hickey GW; Keebler ME; Huston JH; McNamara DM; Mathier MA; Wang Y; Kaczorowski DJ
    J Heart Lung Transplant; 2023 Jan; 42(1):76-86. PubMed ID: 36182653
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Results of new-generation intrapericardial continuous flow left ventricular assist devices as a bridge-to-transplant.
    Carrozzini M; Bejko J; Gambino A; Tarzia V; Lanera C; Gregori D; Gerosa G; Bottio T
    J Cardiovasc Med (Hagerstown); 2018 Dec; 19(12):739-747. PubMed ID: 30300244
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and durability of central oversewing for treatment of aortic insufficiency in patients with continuous-flow left ventricular assist devices.
    Schechter MA; Joseph JT; Krishnamoorthy A; Finet JE; Ganapathi AM; Lodge AJ; Milano CA; Patel CB
    J Heart Lung Transplant; 2014 Sep; 33(9):937-42. PubMed ID: 24997496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.
    Ko BS; Drakos S; Kfoury AG; Hurst D; Stoddard GJ; Willis CA; Delgado JC; Hammond EH; Gilbert EM; Alharethi R; Revelo MP; Nativi-Nicolau J; Reid BB; McKellar SH; Wever-Pinzon O; Miller DV; Eckels DD; Fang JC; Selzman CH; Stehlik J;
    J Heart Lung Transplant; 2016 Aug; 35(8):1024-30. PubMed ID: 27316382
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Markers of inflammation in recipients of continuous-flow left ventricular assist devices.
    Grosman-Rimon L; McDonald MA; Jacobs I; Tumiati LC; Pollock Bar-Ziv S; Shogilev DJ; Mociornita AG; Ghashghai A; Chruscinski A; Cherney DZ; Rao V
    ASAIO J; 2014; 60(6):657-63. PubMed ID: 25232767
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trends and Cost of Heart Transplantation and Left Ventricular Assist Devices: Impact of Proposed Federal Cuts.
    Patel N; Kalra R; Doshi R; Bajaj NS; Arora G; Arora P
    JACC Heart Fail; 2018 May; 6(5):424-432. PubMed ID: 29724365
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impairments in Blood Pressure Regulation and Cardiac Baroreceptor Sensitivity Among Patients With Heart Failure Supported With Continuous-Flow Left Ventricular Assist Devices.
    Sailer C; Edelmann H; Buchanan C; Giro P; Babcock M; Swanson C; Spotts M; Schulte M; Pratt-Cordova A; Coe G; Beindorff M; Page RL; Ambardekar AV; Pal JD; Kohrt W; Wolfel E; Lawley JS; Tarumi T; Cornwell WK
    Circ Heart Fail; 2021 Jan; 14(1):e007448. PubMed ID: 33464953
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Implantable left ventricular assist device. Approaching an alternative for end-stage heart failure. Implantable LVAD Study Group.
    McCarthy PM; James KB; Savage RM; Vargo R; Kendall K; Harasaki H; Hobbs RE; Pashkow FJ
    Circulation; 1994 Nov; 90(5 Pt 2):II83-6. PubMed ID: 7955290
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Echocardiographic Evaluation of Hemodynamics in Patients With Systolic Heart Failure Supported by a Continuous-Flow LVAD.
    Estep JD; Vivo RP; Krim SR; Cordero-Reyes AM; Elias B; Loebe M; Bruckner BA; Bhimaraj A; Trachtenberg BH; Ashrith G; Torre-Amione G; Nagueh SF
    J Am Coll Cardiol; 2014 Sep; 64(12):1231-41. PubMed ID: 25236515
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Left Ventricular Assist Devices.
    Sparrow CT; Nassif ME; Raymer DS; Novak E; LaRue SJ; Schilling JD
    JACC Heart Fail; 2015 Dec; 3(12):956-64. PubMed ID: 26577618
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of Renal Outcomes in Patients With Left Ventricular Assist Device and Heart Transplantation.
    Arshad A; Kew EP; Lim S
    Transplant Proc; 2019 Dec; 51(10):3395-3398. PubMed ID: 31810507
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Unique Blood Pressures and Pulsatility of LVAD Patients: Current Challenges and Future Opportunities.
    Castagna F; Stöhr EJ; Pinsino A; Cockcroft JR; Willey J; Reshad Garan A; Topkara VK; Colombo PC; Yuzefpolskaya M; McDonnell BJ
    Curr Hypertens Rep; 2017 Oct; 19(10):85. PubMed ID: 29043581
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of cardiac resynchronization therapy on clinical outcomes in patients with continuous-flow left ventricular assist devices.
    Gopinathannair R; Birks EJ; Trivedi JR; McCants KC; Sutton BS; Deam AG; Slaughter MS; Hottigoudar RU
    J Card Fail; 2015 Mar; 21(3):226-32. PubMed ID: 25528199
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
    J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immediate recovery of acquired von Willebrand syndrome after left ventricular assist device explantation: implications for heart transplantation.
    Davis ME; Haglund NA; Tricarico NM; Matafonov A; Gailani D; Maltais S
    ASAIO J; 2015; 61(1):e1-4. PubMed ID: 25251586
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Effect of Continuous-Flow Left Ventricular Assist Device Duration on Postoperative Outcomes.
    Chauhan D; Okoh AK; Haik N; Kang N; Choi M; Baran D; Zucker M; Camacho M; Russo MJ
    Ann Thorac Surg; 2017 Dec; 104(6):1933-1938. PubMed ID: 28964413
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prolonged continuous-flow left ventricular assist device support and posttransplantation outcomes: A new challenge.
    Fukuhara S; Takeda K; Polanco AR; Takayama H; Naka Y
    J Thorac Cardiovasc Surg; 2016 Mar; 151(3):872-880.e5. PubMed ID: 26896362
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Arterial pulsatility improvement in a feedback-controlled continuous flow left ventricular assist device: an ex-vivo experimental study.
    Bozkurt S; van Tuijl S; Schampaert S; van de Vosse FN; Rutten MC
    Med Eng Phys; 2014 Oct; 36(10):1288-95. PubMed ID: 25066581
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Erythrocyte aging as a mechanism of anemia and a biomarker of device thrombosis in continuous-flow left ventricular assist devices.
    Taimeh Z; Koene RJ; Furne J; Singal A; Eckman PM; Levitt MD; Pritzker MR
    J Heart Lung Transplant; 2017 Jun; 36(6):625-632. PubMed ID: 28396088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.